Exploring the Human Brain's Structural and Functional Complexity: Current Developments in Neuroscience, Molecular Mechanisms, and Consequences for Health and Neurological Conditions

Padmini Sharma[1], Avneet Gupta[1*], Sidhant Sharma[1*]

1. Department of Pharmacology, LR institute of pharmacy, Solan, HP-173223 India

***Address of Correspondence:**
Dr. Avneet Gupta,
Mr. Sidhant Sharma,
Department of Pharmacology, LR institute of pharmacy, Solan, HP-173223 India

Email: avneet3083@gmail.com
sidhantsharmajmi@gmail.com
psharma8667@gmail.com

ABSTRACT:

This review will concentrate on neural networks, which rewire themselves throughout life in response to experience; the remarkable architecture of key brain regions; and the tiny mechanisms that keep our brains working, such as calcium ion movement, gene activity switches, small regulatory microRNAs, and crucial signals that support nerve cells. From our most profound emotions to our most advanced thoughts and behaviours, the human brain is an extraordinarily dynamic and complex organ. Our knowledge of the composition and operation of the brain has significantly increased as a result of recent developments in artificial intelligence, optogenetics, and neuroimaging.These discoveries are opening the door for new treatments as well as revealing the causes of diseases like Parkinson's, Alzheimer's, and autism spectrum disorders. This review emphasises new treatments and the value of continuing neuroscience research in preserving and regaining brain health by integrating structural, functional, and molecular viewpoints.

Keywords: *Neurodegenerative diseases, neuroplasticity, neuroimaging, molecular mechanisms, epigenetics, connectomics, and artificial intelligence*

1. INTRODUCTION:

1.1 Importance of Studying the Human Brain

The human brain is the true mastermind behind our body, controlling everything from our ideas and behaviors to our awareness and emotions. Neurological and mental conditions, from schizophrenia and depression to Alzheimer's and Parkinson's, affect over a billion individuals

globally. Fighting this disease requires deciphering the biological code that underlies our ideas and emotions, therefore it is not only an intellectual pursuit. [1–3]. Because of our growing understanding of the structure and function of the brain, we are poised to make amazing advancements: personalized treatments for each patient, seamless brain-machine interfaces that could potentially restore lost abilities, and powerful artificial intelligence tools that can learn from the brain's connectivity. In addition, the brain's remarkable plasticity—its ability to change—offers promising pathways for recovery after disease or trauma. Rapidly evolving sciences like neuroinformatics (big-data approaches to brain science), connectomics (the study of the brain's wiring map), and molecular neuroscience are revealing new aspects of this endlessly intriguing organ. [4-10]

2. OVERVIEW OF STRUCTURAL AND FUNCTIONAL COMPLEXITY OF THE HUMAN BRAIN

With about 86 billion nerve cells and an equal number of support cells, our brains are incredibly busy organs. These cells are connected by about 100 trillion synapses, which create an incredibly complex network.[11]. Consider the brain as a busy city, with its cells arranged into districts and neighborhoods, each dedicated to a specific task, ranging from our most ambitious thoughts to the automatic rhythms that keep our hearts and lungs beating. There are four primary "boroughs" in this city, each with a unique area of expertise. Our thinking, sensing, and movement center, the cerebral cortex, is separated into frontal, parietal, temporal, and occipital lobes and extends out like a vast metropolis. It is directly below the limbic system, the emotional center that drives motivation and memories. Whereas the cerebellum perfects our balance and coordination, making sure every step and gesture is precise, the brainstem serves as the city's utility hub, maintaining vital processes like breathing and heartbeat.[12]. Consider the limbic system to be the emotional command center of your brain. The amygdala sounds the alarm and assigns emotional significance to experiences, while the hippocampus serves as an archivist, organizing memories.[13]. The brainstem and cerebellum, on the other hand, function behind the scenes like life's backstage crew, regulating our heartbeat and breathing and perfecting every motion, from a simple nod to a beautiful dance.[14].

Think of the brain as a well-coordinated group of experts: each area specializes in something different (for example, language in one area, vision in another), but they all communicate constantly via extensive neural highways. We can listen in on these discussions using methods like fMRI and EEG, which show constantly changing connections that underpin everything from staying awake and conscious to picking up new skills and maintaining focus.[15–16]. Furthermore, our brains are incredibly flexible and functionally rich due to a superpower known as neuroplasticity, which allows them to rewire and reshape their own networks in response to new experiences, injuries, or changes in our environment..[17]. This adaptability is what enables us to recover from disease or trauma and to learn and develop throughout our lives. While powerful imaging techniques like MRI, DTI, and PET scans provide us with a window into the structure and function of the brain without ever opening a skull, cutting-edge fields like connectomics are vying to map every nuance of our neural wiring. [18–20].

2.1 Functional dynamics and neuroplasticity

Because of their remarkable adaptability, our brains are always changing—creating new connections, rerouting existing ones, and even rewiring entire networks in response to experiences, lessons learned, and healing. Neuroplasticity is a remarkable ability that supports everything from learning a new skill to recovering from an injury. [21]

Synaptic plasticity, or the ability of individual connections between neurons (synapses) to become stronger or weaker over time, is at the core of neuroplasticity. Consider each synapse as a crossroads: the more electrical signals (or traffic) that flow through it, the more resilient and worn out that path gets. This process, known as Long-Term Potentiation (LTP), is how we solidify new knowledge and preserve memories. Conversely, pathways with little traffic gradually deteriorate—Long-Term Depression (LTD)—to prevent our brains from becoming overloaded with obsolete connections.[22]

Together, these dynamic processes enable our minds to remain adaptable, taking in new information, changing with the times, and recovering from injuries. This makes the brain one of nature's most amazing engineering marvels. [23].

2.2 Structural Plasticity

Our brains have the ability to rewire themselves on a larger scale, creating entirely new networks and growing new neurons, going beyond simply adjusting the strength of preexisting connections. In areas like the hippocampus, where new neurons are formed to aid in learning and memory, and during critical developmental windows (think childhood and adolescence), this "structural plasticity" is particularly active. We can use these growth processes after an injury or illness, though they are most noticeable in the early stages of life. This allows the brain to repair itself after damage. [25–26].

2.3 Neuroplasticity in Learning and Memory

Your brain literally changes its structure when you learn something new, strengthening connections that already exist and even creating new neural pathways to help you remember it. To put it another way, neuroplasticity allows your brain to adjust which circuits become stronger and which gradually weaken, which has a direct impact on how well you retain the knowledge you have acquired. [27–28]. Like your brain's memory workshop, the hippocampus works hard to fortify important connections so you can retain experiences over time. [29].

2.4 Neuroplasticity and Recovery from Injury

Healthy parts of the brain take over and rewire themselves to restore lost abilities after a stroke or other severe brain injury. This process is known as neuroplasticity, and it works like an internal repair crew.[30]. Following neurological damage, rehabilitation techniques that take

advantage of neuroplasticity—think focused exercises and brain-training exercises—have been demonstrated to help patients regain their ability to move and think.[31].

3. MOLECULAR MECHANISMS IN BRAIN FUNCTION

Behind it all, every thought, emotion, and memory is driven by microscopic chemical exchanges in our brains. Imagine a vast network of messengers that work together to keep everything functioning properly: neurotransmitters carrying notes between neurons, signaling molecules zipping inside cells, and genes flipping switches. Learning, memory, and even neurological issues can be disrupted when these molecular conversations become jumbled or diverge.[32]

3.1 Epigenetics and Gene Expression

Consider epigenetic modifications as the highlighters and sticky notes that tell the cell which books to read in your enormous library of DNA. Histone modification and DNA methylation, two of the most significant "sticky-note" systems, alter how genes are used without altering the genetic code itself. Your brain depends on these indicators when you acquire new information or create a memorable experience. Histone acetylation, for instance, is like turning pages of a book—genes that support the development of stronger neural connections are given the all-clear to be read and acted upon.. DNA methylation, on the other hand, disables genes that might otherwise promote excessive or harmful growth, much like putting "do not read" stickers on specific pages. These on/off tags work together to direct the development of new synapses and neurons, assisting your brain in adapting, learning, and remembering. [33–34].
A deeper understanding of the brain's epigenetic regulation has enabled new therapeutic approaches, especially in the context of neurodegenerative diseases like Alzheimer's disease, where gene activation or silencing may impact the progression of the illness [35–36].

3.2 MicroRNAs in Brain Function

Consider microRNAs as your cells' tiny traffic controllers. They are non-coding, tiny RNA molecules that quickly intervene, attach to messenger RNAs, and efficiently halt the synthesis of proteins. These microscopic regulators have an impact on important brain functions like neurogenesis (the production of new neurons), synaptic plasticity (the formation of new connections), and inflammation regulation.

Two microRNAs, for instance, miR-132 and miR-212, function as master conductors for memory and synaptic health, adjusting the signals that aid in learning and memory. Even the smallest molecular actors can have a significant impact on brain health, as evidenced by the correlations between diseases like Alzheimer's and Parkinson's and developmental disorders when the balance of these microRNAs changes.[37–38].

These tiny microRNA "switches" in the brain present intriguing opportunities for diseases like Alzheimer's, Huntington's, and autism spectrum disorders. They may serve as biomarkers, or

early warning indicators, or as possible targets for novel therapies that could gently restore balance to gene activity..[39].

3.3 Neurotrophic Factors and Synaptic Plasticity

Consider neurotrophic factors—particularly Brain-Derived Neurotrophic Factor, or BDNF—as the brain's fertilizer, fostering the growth, specialization, and well-being of neurons. Because it enhances long-term potentiation (LTP), which fortifies synaptic connections, BDNF is a memory and learning superpower. The importance of this "growth booster" for mental health and cognition is highlighted by the fact that when BDNF levels fall, as they frequently do in depression, schizophrenia, and Alzheimer's disease, those essential growth and communication pathways may deteriorate.[40–42].

Consider BDNF's assistants, GDNF (glial cell line-derived neurotrophic factor) and NGF (nerve growth factor), as members of the same brain garden crew. NGF directs the growth and survival of important nerve cells, whereas GDNF feeds dopamine neurons and support cells. Together, they preserve neuronal health and the brain's plasticity, or ability to adapt. [43–44].

3.4 Calcium Signaling and Synaptic Transmission

In our brains, calcium ions function as microscopic messengers, flipping switches that regulate everything from sending signals across synapses to turning genes on and off. The processes of LTP and LTD, which are responsible for learning and memory, are initiated when calcium floods neurons. However, calcium can flood the system when this delicate balance goes awry, as it frequently does in diseases like Alzheimer's, causing synaptic damage and even neuron death. This helps explain some of the memory loss and cognitive decline we observe in these conditions.[45–47].

On the surface of every neuron, NMDA receptors act as gatekeepers, meticulously regulating when calcium can flood in. For learning and memory to occur, this calcium entry is essential for creating new connections and reshaping existing ones. The brain's capacity to adapt and create healthy neural circuits can be interfered with when these gatekeepers aren't functioning correctly, as is the case with disorders like autism and schizophrenia. [48–49].

Table: Key Molecular Mechanisms Underlying Brain Function and Their Clinical Relevance

Mechanism	What It Does	Why It Matters	Impact on Brain Disorders	Key References
Epigenetics and Gene Expression	Epigenetic changes like DNA methylation and histone	These processes affect how neurons develop, connect, and store	Unbalances are linked to diseases like Alzheimer's, where	Sweatt, J. D. (2013).

Mechanism	What It Does	Why It Matters	Impact on Brain Disorders	Key References
	modification activate or deactivate genes without altering the DNA itself.	long-term memories. .	gene expression becomes dysregulated. .	
MicroRNAs (miRNAs)	small RNA molecules that control the production of proteins by blocking messenger RNAs.	They lower inflammation, control brain growth, and help create new synapses.	Alterations in miRNA levels have been connected to Huntington's disease, autism, and Alzheimer's disease.	Hansen, K. F., & Obrietan, K. (2013)
Neurotrophic Factors	Proteins like NGF, GDNF, and BDNF help neurons survive, grow, and form new connections.	essential for learning, memory, and mental health by maintaining strong and adaptable brain networks.	Low levels have been connected to depression, schizophrenia, and neurodegenerative diseases. .	Martinowich, K., & Lu, B. (2008)
Calcium Signaling	Calcium ions function as messengers that start neuronal transmission within brain cells.	vital for learning and memory since it encourages synaptic plasticity.	Inappropriate calcium signaling contributes to schizophrenia and Alzheimer's disease and can result in cell death. .	Moghaddam, B., & Javitt, D. (2012).

Our exploration of the chemistry and wiring of the brain is not merely a scholarly endeavor; it has practical implications for identifying, treating, and even preventing a variety of neurological conditions. Developmental difficulties, mental health conditions, or neurodegenerative diseases can arise when the delicate dance of molecules and circuits goes awry. The main brain-related disorders will be highlighted in this section, along with how the most recent developments in neuroscience are changing our knowledge of their causes and paving the way for creative treatments.

The primary cause of dementia, Alzheimer's disease, is characterized by tangled tau strands and sticky amyloid-β clusters that clog neurons and cause persistent inflammation in the brain. Age, lifestyle, and environment all have an impact, but genetics can tip the scales. The most well-known example is the APOE-ε4 variant, which increases the likelihood of those harmful plaques and tangles forming..[48–49].

Recent studies are also shedding light on how Alzheimer's disease can cause inflammation to run amok and exacerbate the condition by rupturing the blood-brain barrier, the brain's defense mechanism. In an effort to slow or even stop Alzheimer's disease in its tracks, researchers are currently looking into creative ways to remove those tenacious tau tangles and amyloid-β clumps and to reduce the harmful inflammation.[50–51]. Immunotherapies and "growth formula" molecules like BDNF are being tested in recent clinical trials for individuals with early-stage Alzheimer's disease, and the preliminary findings are encouraging..[52].

Parkinson's disease is characterized by motor difficulties, including stiffness, tremors, and slowed movements (bradykinesia). It's as if the brain's "dopamine factory" in the substantia nigra begins to shut down—those essential dopamine-producing neurons die off. The disease process is caused by the slow accumulation of misfolded alpha-synuclein proteins, which clump together to form Lewy bodies and gum up neurons. [53].

According to a recent study, Parkinson's disease may be triggered by an imbalance in our gut flora, and the "gut–brain axis" functions as a secret communication channel that influences how the illness develops..[54]. The majority of Parkinson's treatments currently focus on increasing the brain's diminishing dopamine supply in order to control symptoms, while researchers are working on more futuristic solutions like gene therapy, stem cells, and strategies to avoid those problematic alpha-synuclein clumps. [55–56].

Individuals on the autism spectrum frequently struggle with social give-and-take, develop repetitive or comforting routines, and have unique sensory perceptions of the sights, sounds, and textures of the outside world. The communication between the amygdala, our emotion center, and the prefrontal cortex, our decision-making center, is wired slightly differently, according to brain imaging, which could help explain those social and sensory difficulties..[57]. Numerous genes that support the function of our synapses have been identified by genetic research, including Shank3, which is essential for memory formation and the fine-tuning of those crucial neural connections. [58].

Experts believe that abnormalities in the brain's growth signals, malfunctions in the connections and firing of neurons, and modifications in the development of new nerve cells could be the cause of autism spectrum disorder..[59]. The majority of modern treatments still rely on behavioral therapies, which assist patients in developing routines, skills, and strategies for everyday life, even as researchers investigate new drugs that alter the chemistry of the brain—think medications that reduce excessive glutamate signaling or channel the socially enhancing effects of oxytocin. [60–61].

The hallmarks of schizophrenia, a chronic mental illness, include hallucinations, delusions, and cognitive impairment. Dysregulated dopamine signaling, specifically in the mesolimbic and mesocortical pathways, is a major contributing factor to the pathophysiology of schizophrenia. Moreover, NMDA receptor dysfunction is connected to the disorder's cognitive abnormalities.[62–63].

Recent research indicates that schizophrenia may be caused by a disruption in the brain's capacity to grow new neurons (neurogenesis) and rewire itself (synaptic plasticity), particularly during the tumultuous adolescent years. The majority of people with schizophrenia still use conventional antipsychotic drugs to treat their symptoms, even though researchers are creating new medications that alter glutamate signaling or reduce harmful inflammation in the brain (and these look promising for patients who don't respond to standard treatments). [65–66].

The protective layer (myelin) surrounding nerve fibers is mistakenly targeted by the body's immune system in multiple sclerosis, causing inflammation and progressive nerve damage. This "friendly fire" causes a variety of mental and physical difficulties, ranging from memory and concentration problems to muscle weakness and coordination issues. This attack is fueled by rogue T-cells and hyperactive microglia, the brain's cleanup cells, according to recent research, which raises the possibility of novel strategies to suppress the immune system and shield those delicate nerves.[67–68].

The goal of today's treatments is to control the immune system and safeguard nerve cells. More recent methods seek to reduce inflammation, aid in the restoration of the damaged myelin sheath, and address the underlying cause of the immune system's misguided reaction. [69–70].

4. IMPLICATIONS FOR NEUROLOGICAL DISORDERS

Recent advances in our understanding of the complex wiring, chemistry, and function of the brain have allowed us to make significant progress in the treatment of neurological disorders. This section examines how these discoveries are changing our understanding of serious illnesses like Alzheimer's, Parkinson's, and autism spectrum disorder—and creating opportunities for more effective therapies.

4.1 Alzheimer’s Disease

Alzheimer's disease causes the brain's circuits that allow you to create and recall memories to become clogged with tangled tau fibers and sticky amyloid-β clumps. Meanwhile, the damage is fueled by oxidative stress and a simmering inflammation. Carrying the APOE-ε4 gene variant only increases the risk of developing the disease, and recent research indicates that overzealous microglia—the brain's cleanup crew—can actually exacerbate this fire..[71–72]. Alzheimer's disease affects not only the plaques and tangles that clog your brain, but also the systems that keep your neurons flexible and healthy. Brain-Derived Neurotrophic Factor (BDNF) and its partner TrkB support the growth of new neurons and the fortification of existing connections in a healthy brain. However, both of these essential "growth signals" become weaker in Alzheimer's, impairing the brain's innate capacity for memory, learning, and self-healing.. [73–74].

In an effort to slow or even reverse the memory and cognitive issues associated with Alzheimer's disease, researchers are currently focusing on treatments such as immunotherapies

and neuron-protecting medications that work to remove tau tangles and amyloid plaques from the brain and reduce damaging inflammation.. [75–78].

4.2 Parkinson’s Disease

Parkinson's disease starts when the substantia nigra, a region of the brain that produces dopamine, begins to die off, impairing our ability to move normally. To make matters worse, those sticky alpha-synuclein proteins aggregate into Lewy bodies, which further clog neurons and accelerate the progression of the illness.

[79–81]. According to a new line of research, our gut is home to trillions of microbes that communicate with the brain via the "gut–brain axis," suggesting that it is more than just a food processor. These microscopic tenants have the ability to alter inflammation and nerve-cell health, and it appears that this back-and-forth may contribute to the development of Parkinson's disease.[82–84].

The goal of modern, state-of-the-art therapies is to restore dopamine function. Gene therapies and neuroprotective medications aim to protect and restore those dopamine-producing neurons, while deep brain stimulation (DBS) "jump-starts" motor circuits using tiny implanted electrodes. Even more intriguing, preliminary research indicates that administering GDNF to the brain—imagine it as a specific “fertilizer” for neurons—may aid in the recovery and function restoration of damaged cells. [85–89].

4.3 Autism Spectrum Disorder

The brain's "wiring" is slightly different in autism spectrum disorder, which shows up as intense interests, repetitive routines, and difficulties with reciprocal social cues. Subtle changes in areas such as the cerebellum (which aids in attention and movement coordination), the amygdala (the emotion center), and the prefrontal cortex (our decision-making center) are frequently detected by brain scans. The distinctive strengths and difficulties of individuals on the spectrum are thought to be shaped by a combination of low-grade inflammation, altered neuroplasticity (the way the brain rewires itself), and modifications in synaptic communication.. [90–93]. Recent brain scans indicate that less fluid "communication highways" between important brain regions may be the cause of autism's cognitive and social difficulties. Researchers are currently testing early interventions intended to improve synaptic connections and increase the brain's growth signals in order to help close those gaps. This effectively gives the neural network a head start in creating stronger, more adaptable pathways [94–99].

4.4 Multiple Sclerosis

The immune system of the body malfunctions in multiple sclerosis, removing the myelin sheath that surrounds nerve fibers. Imagine this as insulation removing electrical wires. This slows or stops signals from the brain to the body. The brain's "security guards," or overactive microglia, and rogue antibodies that target myelin proteins are two factors contributing to this attack.

Since the damage is continuously being fueled by a simmering inflammation in the nervous system, glial cell activation and neuroinflammation are key factors in the development of multiple sclerosis.

In order to specifically target the immune cells causing inflammation in multiple sclerosis, researchers have created therapies such as monoclonal antibodies. These treatments seek to lessen harm and soothe the immune system. Simultaneously, scientists are investigating neuroprotective medications and remyelination treatments, which are intended to help heal the damaged myelin and shield nerve cells from further deterioration. [100–104].

5 RECENT ADVANCES IN NEUROSCIENCE

Modern tools, teams spanning biology and engineering, and a closer examination of the brain from the smallest molecular switches to complex thoughts are all driving the neuroscience revolution we are currently experiencing. This section will discuss some of the revolutionary technologies that are revolutionizing both laboratory research and clinical care, such as ultra-high-resolution imaging, optogenetics, which uses light to turn neurons on and off, sophisticated brain-computer interfaces, and AI-powered data analysis.

5.1 Connectomics: Mapping the Brain’s Network

Consider connectomics to be neuroscience's version of a big city map, mapping every road and alleyway in the brain's wiring. Researchers have discovered the "street map" and the real-time information flow between regions by using sophisticated scans like fMRI to listen in on live traffic and DTI to trace the actual roads. Major hubs—bustling intersections that maintain our memory and sharpness of thought—have been identified along the way. The brain's communication network can become disrupted in conditions like autism, bipolar disorder, and schizophrenia when these hubs or their connecting pathways malfunction.[105–108]. We may eventually find the biological markers that indicate mental health problems and neurodegenerative diseases early on by mapping these neural highways.[108]

5.2 Optogenetics: Light-Based Control of Neurons

The power of optogenetics is like having a remote control for your brain. By inserting light-sensitive proteins into particular neurons, scientists can use light to precisely turn those neurons on or off in real time. In animal studies, this "neural flashlight" has revealed the workings of circuits that control memory, learning, reward, and even addiction. Furthermore, light-guided stimulation of motor circuits in Parkinson's models has demonstrated genuine promise in reducing stiffness and tremors, suggesting that future treatments may actually turn symptoms on and off with light.[109].

5.3 Artificial Intelligence (AI) and Machine Learning in Neuroscience

We can now analyze vast amounts of brain data in ways that were unimaginable only a few years ago, thanks to developments in artificial intelligence and machine learning. In just a few seconds, intelligent algorithms can sort through neuroimaging scans, identifying minute patterns that aid in quicker diagnosis, individualized treatment plans, and even disease prognostication. For example, long before symptoms of Alzheimer's and other neurodegenerative diseases become evident, deep learning models are already interpreting MRI scans to detect the first signs of these conditions..[110–112]. Artificial intelligence (AI) tools can now function as a personalized crystal ball by combining a person's genetic blueprint, brain scans, and medical history to predict how a disease might progress and which treatments are most likely to benefit each individual.[113]. Researchers are accelerating the development of better treatments by using AI's data-crunching power to pinpoint new treatment targets and find biomarkers, or early warning signs, for diseases like multiple sclerosis and epilepsy.

5.4 Stem Cells and Neuroregeneration

Research on stem cells is creating innovative new avenues for the treatment of disorders affecting the brain and spinal cord. Stem cells have the potential to restore damaged tissue and regenerate lost neurons in diseases like Parkinson's, Alzheimer's, stroke, and spinal cord injury. We can even rewind a patient's own cells to an embryonic state and use induced pluripotent stem cells, or iPSCs, to create the very neurons or support cells that are impacted by their illness. This enables researchers to test possible medications on cells that contain the patient's distinct genetic composition and investigate the molecular causes of neurological disorders in a dish. Regarding therapy, iPSCs are opening the door for cell-based treatments that may eventually replace damaged neurons and activate the body's inherent healing mechanisms.[114–118].

5.5 Neuroscience of Aging: From Cognitive Decline to Neurodegeneration

Our brains change as we age; small changes accumulate over time, making everything from memory to mobility a little more difficult. Because of this, researchers are focusing on the "biological clocks" of aging and the mechanisms that can tip the scales in favor of neurodegeneration, such as oxidative stress damage, deteriorating mitochondria (the powerhouses of our cells), and creeping inflammation. Researchers aim to slow or even prevent the cognitive decline and diseases like Parkinson's and Alzheimer's that become more prevalent with age by comprehending these age-related changes.[119]

The impact of neuroplasticity on aging has also been the subject of recent studies. The brain's ability to reorganize and form new connections decreases with age, but strategies that increase neuroplasticity, such as cognitive training, physical exercise, and dietary interventions, have shown promise in lowering the risk of neurodegenerative diseases and mitigating cognitive decline. [110].

6. IMPLICATIONS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The way we identify, treat, and even prevent neurological and mental health disorders is already changing as a result of our growing understanding of the chemistry and wiring of the brain. In addition to examining the state-of-the-art technologies that are improving patient outcomes, such as AI diagnostics, optogenetics, and stem-cell therapies, we will also dissect the fundamental molecular and circuit-level alterations that underlie conditions like Alzheimer's, Parkinson's, multiple sclerosis, autism, and schizophrenia.

6.1 Alzheimer’s Disease (AD)

Memory loss, confused thinking, and unexpected behavioral changes are all signs of Alzheimer's disease. The cause of this decline is twisted tau tangles and sticky amyloid-β plaques, which clog synapses and eventually cause neuron death. Your genetic composition can tip the scales in favor of increased risk, particularly if you have the APOE ε4 variant. We can now actually see those plaques and tangles in living brains because of advancements in PET scan technology. Furthermore, inflammation is sparked by blood-brain barrier leaks and an overzealous cleanup crew of microglia, which exacerbates the damage.[111]
The goal of current Alzheimer's treatments is to reverse the trend in the following ways:
• Targeted antibodies: Medication such as aducanumab removes the sticky amyloid-β plaques that clog the brain's wiring like specialized brooms.
• Tau blockers: Also known as "anti-knot" agents for your neurons, researchers are creating substances that prevent tau proteins from grouping together to form harmful tangles.
• Modifications to lifestyle: Simple lifestyle modifications, such as consistent exercise, a heart-healthy diet, restful sleep, and mental stimulation, can help postpone the onset of the disease and give your brain more time to remain healthy.

6.2 Parkinson’s Disease (PD)

Parkinson's disease causes the classic symptoms of stiffness, tremors, slowed movement (bradykinesia), and balance issues as if the brain's "dopamine factory" in the substantia nigra slowly shuts down—those essential dopamine-producing cells die off. Under a microscope, you can see Lewy bodies, which are clusters of the protein alpha-synuclein that further impair neuronal function.

- Recent discoveries are illuminating the disease's causes and offering novel therapeutic approaches:
- Genetic hints: Gene mutations in LRRK2, PARK7, and PINK1 have been connected to familial forms of Parkinson's disease, which helps us understand why certain individuals are at higher risk.

  • The gut-brain connection: Research indicates that an imbalance in gut flora and signals along the "gut–brain axis" may cause Parkinson's disease to develop or worsen, potentially leading to new treatments that target the digestive tract.

• Next-generation therapies: In addition to conventional drugs, scientists are looking into cell-based therapies to replace lost neurons and deep brain stimulation (DBS), which uses tiny electrodes implanted in the brain to "jump-start" motor circuits and reduce symptoms.[112-113].

6.3 Autism Spectrum Disorders (ASD)

Communication difficulties, a fondness for routines or repetitive behaviors, and social nuances are some of the neurodevelopmental differences associated with autism spectrum disorder. Subtle changes in cortical thickness and odd wiring within the brain's "default mode network"—the areas we use when daydreaming or reflecting on ourselves—are frequently visible on brain scans.

Genetically speaking, autism has been associated with mutations in important genes such as SHANK3, MECP2, and CNTNAP2, which indicate abnormalities in the way synapses communicate and the way the immune system functions in the brain. To support the distinct needs and strengths of individuals on the spectrum, researchers are currently conducting trials on a variety of treatments, including neurofeedback, customized behavioral therapies, and oxytocin-based therapies (which tap into the "social hormone").[114–116].

6.4 Depression and Mood Disorders

Serotonin, dopamine, and norepinephrine imbalances, slow neural rewiring (neuroplasticity), and chronic inflammation in the brain are all factors in depression, which is more than just feeling depressed. Brain scans frequently show underactive areas of the brain that are involved in focus and decision-making, like the prefrontal and anterior cingulate cortices, as well as overactive emotion centers, like the amygdala.

There are some revolutionary developments in the field of treatment. Fast-acting medications, such as ketamine, its mirror molecule esketamine, and even psilocybin in guided therapy sessions, act on NMDA receptors to provide immediate relief, while noninvasive brain-stimulation techniques like transcranial magnetic stimulation (TMS) can "zap" underperforming areas back into gear. Furthermore, it's intriguing to note that recent studies on the gut-brain axis indicate that the trillions of microorganisms in our digestive tract may also hold the secret to improving our mood. [117–119].

6.5 Schizophrenia

Schizophrenia can cause distressing symptoms, such as delusions, hallucinations, and difficulty thinking clearly, that last a lifetime. It can also feel like your brain's "signal stations" are out of sync. While fMRI demonstrates that the networks intended to communicate with one another aren't always on the same wavelength, brain scans reveal that some of the gray matter itself shrinks in specific areas.

Currently, scientists are identifying the genetic causes of the disorder, identifying risk variations dispersed throughout several chromosomes, and determining the roles of the immune system, dopamine circuits, and glutamate signaling. Furthermore, doctors are now able to predict which patients will benefit from particular treatments the most and even how a patient's condition may change over time with the aid of advanced AI tools. [120–121].

7. FUTURE DIRECTION & CONCLUSION

7.1 Future Directions

Neuroscience is preparing for a more connected and individualized understanding of brain health in the future. The field is moving in the following direction:

- **Tailored Treatments:** "Precision neuroscience" seeks to create therapies that are customized for each individual, increasing the efficacy and efficiency of mental and neurological treatments by combining everything from behavior and brain scans to genetic profiles.
- **Mind tech ethics**: If we wish to safely assist those with locked-in syndrome, spinal injuries, or ALS, we will need to address important issues regarding identity, privacy, and the boundary between therapy and enhancement as we develop neural implants (think Neuralink) and brain–computer interfaces.
- **Monitoring the Brain Over Time:** Large-scale initiatives such as the Human Connectome Project, the ENIGMA Consortium, and the Brain Initiative are creating long-term maps of the structure and function of the brain. These "big picture" datasets will assist us in identifying disease early warning indicators and may even lead to prevention.
- **Immune–Brain Cross-Talk:** Our understanding of how immune cells affect conditions ranging from multiple sclerosis to mood disorders is still developing. Reducing detrimental inflammation may prove to be a revolutionary approach for a variety of brain disorders.
- **Digital Twins & Computational Models:** Picture a computer simulation driven by artificial intelligence that is a virtual version of your brain. To speed up discoveries and lower risk, researchers could test new medications and therapies in silico before attempting them in real life.

  When combined, these frontiers have the potential to make brain care more intelligent, accurate, and compassionate than it has ever been.

7.2 Conclusion

Determining how our own minds function is still one of science's biggest—and most satisfying—challenges. These days, we do much more than just create brain maps. By combining cutting-edge imaging, molecular biology, artificial intelligence, and genetics, we

are learning the fundamentals of how neurons communicate, why disease-related circuits malfunction, and how to create genuinely revolutionary therapies.

These discoveries help us better understand how the brain works normally and shed light on the causes of a wide range of illnesses, including depression and Alzheimer's. Going forward, the true potential of neuroscience will be found in methods that are as tech-savvy, ethical, and individualized as they are concerned with enhancing people's lives. We are constructing that future, one in which human welfare and state-of-the-art science coexist.

Acknowledgements:

The author expresses sincere gratitude to the faculty of [Lr Institute of Pharmacy]'s Department of Pharmacology for their academic support and direction throughout the writing of this review. Coworkers and library employees are also thanked for providing access to important research databases and journals.

References

1. World Health Organization. (2006). Neurological Disorders: Public Health Challenges. WHO Press.
2. Feigin, V. L., Vos, T., & Nichols, E., et al. (2020). The global burden of neurological disorders: translating evidence into policy. The Lancet Neurology, 19(3), 255–265.
3. GBD 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis. The Lancet Neurology, 18(5), 459–480.
4. Sejnowski, T. J., Churchland, P. S., & Movshon, J. A. (2014). Putting big data to good use in neuroscience. Nature Neuroscience, 17(11), 1440–1441.
5. He, B., et al. (2013). Brain–machine interfaces: Past, present and future. Trends in Neurosciences, 36(9), 486–496.
6. Friston, K. J., et al. (2019). Bayesian approaches to brain function and dysfunction. Neuron, 101(3), 416–434.
7. Pascual-Leone, A., et al. (2005). The plastic human brain cortex. Annual Review of Neuroscience, 28, 377–401.
8. Zatorre, R. J., Fields, R. D., & Johansen-Berg, H. (2012). Plasticity in gray and white: neuroimaging changes in brain structure during learning. Nature Neuroscience, 15(4), 528–536.
9. Sporns, O. (2011). The human connectome: a complex network. Annals of the New York Academy of Sciences, 1224(1), 109–125.
10. Amunts, K., & Zilles, K. (2015). Architectonic mapping of the human brain beyond Brodmann. Neuron, 88(6), 1086–1107.
11. Azevedo, F. A. C., et al. (2009). Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. Journal of Comparative Neurology, 513(5), 532–541.

12. Nieuwenhuys, R., Voogd, J., & van Huijzen, C. (2007). The Human Central Nervous System: A Synopsis and Atlas. Springer.
13. Rolls, E. T. (2015). Limbic systems for emotion and for memory, but no single limbic system. Cortex, 62, 119–157.
14. Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (2013). Principles of Neural Science (5th ed.). McGraw-Hill.
15. Fox, M. D., & Raichle, M. E. (2007). Spontaneous fluctuations in brain activity observed with functional MRI. Nature Reviews Neuroscience, 8(9), 700–711.
16. Friston, K. J. (2011). Functional and effective connectivity: a review. Brain Connectivity, 1(1), 13–36.
17. Kolb, B., & Gibb, R. (2014). Searching for the principles of brain plasticity and behavior. Cortex, 58, 251–260.
18. Sporns, O., Tononi, G., & Kötter, R. (2005). The human connectome: A structural description of the human brain. PLoS Computational Biology, 1(4), e42.
19. Van Essen, D. C., et al. (2013). The WU-Minn Human Connectome Project: An overview. NeuroImage, 80, 62–79.
20. Glasser, M. F., & Van Essen, D. C. (2011). Mapping human cortical areas in vivo based on myelin content as revealed by T1- and T2-weighted MRI. Journal of Neuroscience, 31(32), 11597–11616.
21. Bliss, T. V. P., & Collingridge, G. L. (1993). A synaptic model of memory: Long-term potentiation in the hippocampus. Nature, 361(6407), 31–39.
22. Malenka, R. C., & Bear, M. F. (2004). LTP and LTD: An embarrassment of riches. Neuron, 44(1), 5–21.
23. Morris, R. G. M. (2003). Long-term potentiation and memory. Philosophical Transactions of the Royal Society B: Biological Sciences, 358(1432), 643–647.
24. Kempermann, G., et al. (2015). Functional plasticity of adult hippocampal neurogenesis. Trends in Cognitive Sciences, 19(4), 195–201.
25. Kolb, B., & Gibb, R. (2011). Brain plasticity and recovery from early damage. Developmental Psychobiology, 53(2), 276–284.
26. Cramer, S. C., & Chopp, M. (2000). Repairing the brain. Science, 287(5453), 244–248.
27. Berman, M. G., et al. (2013). Prefrontal cortex and the regulation of emotion. Psychological Science, 24(5), 721–724.
28. Doyon, J., et al. (2009). Contributions of the basal ganglia and functionally related brain structures to motor learning. Behavioral Brain Research, 199(1), 61–75.
29. Kirwan, C. B., & Stark, C. E. L. (2007). Medial temporal lobe activity during encoding and retrieval of novel face-name pairs. NeuroImage, 35(4), 1719–1725.
30. Nudo, R. J. (2006). Neural plasticity and recovery of function. Journal of the American Medical Association, 296(17), 2143–2145.
31. Edwards, D. F., et al. (2011). Neuroplasticity and rehabilitation: The role of physical therapy. Neurology, 77(12), 1170–1179.
32. Day, J. J., & Sweatt, J. D. (2010). Epigenetic mechanisms in cognition. Neuron, 70(5), 815–829.
33. Feng, J., et al. (2015). Epigenetic regulation of neural plasticity and memory. Nature Reviews Neuroscience, 16(5), 276–288.

34. Levenson, J. N., & Sweatt, J. D. (2005). Epigenetic mechanisms in memory formation. Nature Reviews Neuroscience, 6(2), 108–118.
35. Spires, T. L., & Hyman, B. T. (2014). The pathology of Alzheimer's disease: The role of amyloid-β and tau. Current Alzheimer Research, 11(3), 241–248.
36. Gräff, J., & Tsai, L. H. (2013). The potential of epigenetic therapeutics in Alzheimer's disease. Nature Reviews Drug Discovery, 12(11), 795–809.
37. He, L., & Hannon, G. J. (2004). MicroRNAs: Small RNAs with a big role in gene regulation. Nature Reviews Genetics, 5(7), 522–531.
38. Saba, R., et al. (2012). miRNA-132 regulates synaptic plasticity and memory in the mouse hippocampus. The Journal of Neuroscience, 32(21), 7212–7221.
39. McNeill, R. V., & Sillitoe, R. V. (2017). MicroRNAs in the pathophysiology of neurodevelopmental and neurodegenerative diseases. Brain Research Bulletin, 130, 33–42.
40. Lu, B., & Figurov, A. (1997). Neurotrophins and their effects on synapses. Annual Review of Neuroscience, 20, 87–115.
41. Malenka, R. C., & Bear, M. F. (2004). LTP and LTD: An embarrassment of riches. Neuron, 44(1), 5–21.
42. Duman, R. S. (2004). Depression: A neuroplasticity disorder. NeuroScience, 129(1), 209–217.
43. Whittemore, S. R., & Koliatsos, V. E. (1993). Nerve growth factor and glial cell line-derived neurotrophic factor in the central nervous system. The Journal of Neuroscience, 13(10), 4252–4262.
44. Shetty, A. K., & Hattiangady, B. (2007). Glial cell line-derived neurotrophic factor in the adult brain: A promising therapeutic strategy for neurodegenerative disorders. Neurobiology of Disease, 28(3), 281–296.
45. Berridge, M. J., & Lipp, P. (2004). Calcium signaling in neurons. Neurobiology of Disease, 12(2), 185–198.
46. Lim, S. E., et al. (2011). Calcium dysregulation and Alzheimer's disease: The role of calcium in Alzheimer's disease pathogenesis. Neurodegenerative Disease Management, 1(5), 417–428.
47. Dehmelt, L., & Halpain, S. (2005). The MAP2/Tau family of microtubule-associated proteins. Genome Biology, 6(2), 204–215.
48. Murray, M. J., et al. (2009). NMDA receptor function in the pathophysiology of schizophrenia. Journal of Clinical Psychiatry, 70(12), 1644–1652.
49. Zukin, R. S., & Bennett, M. V. (2007). NMDA receptors and synaptic plasticity. Current Opinion in Neurobiology, 17(3), 344–352.
50. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356.
51. Roses, A. D. (2006). Apolipoprotein E and Alzheimer's disease: Risk, mechanisms, and therapy. Current Alzheimer Research, 3(6), 495–503.
52. Cummings, J., et al. (2014). Alzheimer's disease drug development pipeline: 2014. Alzheimer's & Dementia, 10(6), 607–617.
53. Wyss-Coray, T. (2016). Ageing, neurodegeneration and brain rejuvenation. Nature, 539(7628), 180–186.

54. Hampel, H., et al. (2018). A precision medicine approach to Alzheimer's disease. The Lancet Neurology, 17(5), 380–389.
55. Spillantini, M. G., et al. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839–840.
56. Borghammer, P., & Bartels, A. (2016). The role of the gut-brain axis in Parkinson’s disease. The Lancet Neurology, 15(1), 53–64.
57. Kordower, J. H., et al. (2013). Dopamine gene therapy for Parkinson’s disease. Nature, 501(7466), 495–503.
58. Jellinger, K. A. (2012). Neuropathology of Parkinson's disease and Alzheimer's disease. Neurodegenerative Diseases, 10(5), 220–228.
59. Ecker, C., et al. (2010). Neuroimaging in autism spectrum disorders: Brain structure and function. Dialogues in Clinical Neuroscience, 12(4), 453–465.
60. Peca, J., et al. (2011). Shank3 mutant mice display autistic-like behaviors and striatal dysfunction. Nature, 472(7344), 137–142.
61. Courchesne, E., et al. (2011). Autism spectrum disorder. Nature Reviews Disease Primers, 1, 15003.
62. Hollander, E., & Anagnostou, E. (2013). Pharmacologic treatment of autism spectrum disorders. Pediatric Clinics of North America, 60(5), 1055–1074.
63. Modahl, C., et al. (1998). Oxytocin and autism: A new look at the science. Psychiatric Clinics of North America, 21(2), 229–246.
64. Javitt, D. C., & Sweet, R. A. (2015). N-methyl-D-aspartate receptor hypofunction in schizophrenia: Implications for cognition and disease pathophysiology. Molecular Psychiatry, 20(2), 17–29.
65. Muench, J., & Hamer, R. (2010). Neurological and cognitive effects of antipsychotic medications. The Journal of Clinical Psychiatry, 71(6), 937–946.
66. Tamminga, C. A., et al. (2010). The neurodevelopmental hypothesis of schizophrenia. American Journal of Psychiatry, 167(3), 343–355.
67. McCutcheon, R. A., et al. (2019). The role of glutamate in the pathophysiology of schizophrenia. Schizophrenia Bulletin, 45(1), 110–118.
68. Miller, T. J., & Berman, R. M. (2004). Pharmacotherapy for schizophrenia: Emerging therapeutic approaches. Pharmacological Reviews, 56(4), 429–455.
69. Prinz, M., & Priller, J. (2014). Microglia and brain macrophages in the molecular age: From origin to neurodevelopmental disease. Nature Reviews Neuroscience, 15(5), 300–312.
70. Pender, M. P. (2011). Multiple sclerosis and the immune system: A review. Multiple Sclerosis Journal, 17(8), 953–960.
71. Hauser, S. L., et al. (2015). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221–234.
72. Cohen, J. A., et al. (2016). Alemtuzumab for patients with relapsing multiple sclerosis: Results of a phase 2 randomized controlled trial. Lancet Neurology, 15(6), 588–599.
73. Sporns, O., & Betzel, R. F. (2016). Modular brain networks. Annual Review of Psychology, 67, 613–640.
74. Bassett, D. S., & Sporns, O. (2017). Network neuroscience. Nature Neuroscience, 20(3), 353–364.

75. Bullmore, E., & Sporns, O. (2012). The economy of brain network organization. Nature Reviews Neuroscience, 13(5), 336–349.
76. van den Heuvel, M. P., & Sporns, O. (2013). Network hubs in the human brain. Trends in Cognitive Sciences, 17(12), 683–696.
77. Wagstyl, K., et al. (2016). Brain network analysis in schizophrenia: From structural to functional and molecular insights. Neuroscience & Biobehavioral Reviews, 60, 126–141.
78. Deisseroth, K. (2015). Optogenetics: 10 years of microbial opsins in neuroscience. Nature Neuroscience, 18(9), 1213–1225.
79. Tye, K. M., & Deisseroth, K. (2012). Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Reviews Neuroscience, 13(4), 251–266.
80. Esteva, A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.
81. McKinney, S. M., et al. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577(7788), 89–94.
82. Marquand, A. F., et al. (2019). Neuroimaging in psychiatric research: A review of the latest advances in machine learning. Psychiatric Clinics of North America, 42(3), 499–512.
83. Wu, X., et al. (2019). Machine learning in brain imaging: A review on computational methods for neuroimaging data. Journal of Neuroscience Methods, 315, 1–14.
84. Lupski, J. R., & Stankiewicz, P. (2005). Structural variation in the human genome and its role in disease. Annual Review of Medicine, 56, 347–359.
85. Kirov, G., et al. (2012). Copy number variation in schizophrenia. Science, 336(6089), 746–749.
86. Dempster, E. L., et al. (2015). DNA methylation in neurodegenerative diseases: Implications for therapeutic interventions. Trends in Molecular Medicine, 21(10), 649–659.
87. Dempster, E. L., et al. (2017). Environmental and epigenetic factors in neurodegeneration. Current Opinion in Neurology, 30(6), 518–523.
88. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
89. Maeder, M. L., et al. (2013). Targeted genome editing in yeast with the CRISPR/Cas system. PLoS ONE, 8(7), e65358.
90. Heneka, M. T., et al. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, 14(4), 388–405.
91. Lian, H., et al. (2017). Targeting neuroinflammation in Alzheimer's disease: The therapeutic potential of microglial activation modulators. Current Drug Targets, 18(4), 380–394.
92. Pottier, C., et al. (2017). Immunomodulation and gene therapy for Parkinson's disease. Nature Reviews Neurology, 13(6), 373–385.
93. Holtzman, D. M., et al. (2012). APOE and Alzheimer's disease: The influence of genetic variation on risk. Current Alzheimer Research, 9(5), 521–530.
94. Heneka, M. T., et al. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, 14(4), 388–405.

95. Kesslak, J. P., et al. (1997). Brain-derived neurotrophic factor and its potential therapeutic effects in Alzheimer's disease. Journal of Alzheimer's Disease, 8(1), 41–52.
96. Zadori, D., et al. (2020). The role of BDNF-TrkB signaling in Alzheimer's disease. Neurobiology of Disease, 137, 104757.
97. Cummings, J., et al. (2014). Alzheimer's disease drug development pipeline: 2014. Alzheimer's & Dementia, 10(3), 219–232.
98. Reddy, P. H., et al. (2016). Targeting mitochondria for Alzheimer's disease therapeutics. Journal of Alzheimer's Disease, 50(1), 1–14.
99. Spillantini, M. G., et al. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839–840.
100. Goedert, M., et al. (2013). The role of tau in neurodegenerative diseases. Trends in Molecular Medicine, 19(10), 507–514.
101. Sampson, T. R., et al. (2016). Gut microbiota regulates motor deficits and neuroinflammation in a model of Parkinson's disease. Cell, 167(6), 1469–1480.
102. Lang, A. E., & Lozano, A. M. (1998). Parkinson's disease: From basal ganglia to brain-stimulation. Lancet, 352(9137), 493–496.
103. Courchesne, E., et al. (2007). Mapping early brain development in autism. Neuron, 56(2), 399–413.
104. Just, M. A., et al. (2007). The neural basis of social behavior in autism. NeuroImage, 35(1), 246–254.
105. Ecker, C., et al. (2013). Neuroanatomy of autism. Trends in Neurosciences, 36(10), 476–485.
106. Hines, J. H., et al. (2015). Early interventions in autism and related disorders. Journal of Child Psychology and Psychiatry, 56(10), 1080–1091.
107. Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46(4), 907–911.
108. Lassmann, H., et al. (2012). Multiple sclerosis: Pathology and mechanisms. Acta Neuropathologica, 123(4), 247–267.
109. Sospedra, M., & Martin, R. (2005). Immunology of multiple sclerosis. Annual Review of Immunology, 23, 683–747.
110. Bassett, D. S., & Sporns, O. (2017). Network neuroscience. Nature Neuroscience, 20(3), 353–364.
111. Zhang, F., et al. (2006). Optogenetic manipulation of neural circuits in vivo. Nature, 441(7095), 926–931.
112. Fjell, A. M., et al. (2014). The relation between changes in brain volume and Alzheimer’s disease. Neurobiology of Aging, 35(3), 523–534.
113. Kourtzi, Z., et al. (2020). Machine learning in clinical neuroscience: From data to diagnostic and therapeutic decision-making. Nature Reviews Neuroscience, 21(4), 175–187.
114. Kriks, S., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature, 480(7378), 547–551.
115. Thangavel, R., et al. (2013). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases: Implications for therapeutics. Annals of the New York Academy of Sciences, 1276(1), 42–63.

116. Erickson, K. I., et al. (2011). Physical activity, fitness, and neurocognitive function in older adults: An overview of the literature. Neurobiology of Aging, 32(4), 1–8.
117. De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer's disease. Cell, 164(4), 603–615.
118. Poewe, W., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.
119. Lord, C., et al. (2020). Autism spectrum disorder. The Lancet, 392(10146), 508–520.
120. Duman, R. S., et al. (2019). Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research, 8.
121. Howes, O. D., & Murray, R. M. (2014). Schizophrenia: an integrated sociodevelopmental-cognitive model. The Lancet, 383(9929), 1677–1687.